CHRISTOPHER MALYNOWSKI: Open Payments
NPI 1275622565 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,429 in 28 payments from 11 companies in 2025. Trend: 2023 $1,058 · 2024 $1,431 · 2025 $1,429
Food & beverage: $1,429
| Company | Payments | Amount |
|---|---|---|
| Edwards Lifesciences Corporation | 5 | $736 |
| Alnylam Pharmaceuticals Inc. | 6 | $189 |
| SCPHARMACEUTICALS INC. | 1 | $113 |
| Medtronic, Inc. | 1 | $89 |
| PFIZER INC. | 5 | $87 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $85 |
| ABIOMED | 1 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $31 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
Products named: SAPIEN 3 Ultra RESILIA, AMVUTTRA, FUROSCIX, ELIQUIS, COREVALVE EVOLUT R, JARDIANCE, LEQVIO, FARXIGA.
Industry payments across NY — which companies pay providers there.
